We tested the hypothesis whether microRNA-21 (miR-21) can detect CSA-AKI earlier than serum creatinine (sCr). A total of 103 patients scheduled to undergo cardiac surgery. CSA-AKI was defi ned as sCr > 0.3 mg/dl 24 h after surgery. The patients were divided into two groups according to whether or not developing AKI after surgery. Serum and urinary miR-21 were measured prior to, and 6, 12 and 24 h after surgery. Baseline serum and urinary levels of miR-21 in AKI group were lower than in non-AKI group. Moreover, the levels of miR-21 were signifi cantly lower 6 h after surgery for serum, and 6 and 12 h after surgery for urine samples than those before surgery in AKI group. Area under the curve (AUC) of the receiver operating characteristic (ROC) values were 0.81 (95% CI: 0.65-0.97) for serum miR-21 (6 h after surgery), 0.90 (95% CI: 0.79-0.99) for urine (6 h after surgery), and 0.86 (95% CI: 0.71-0.98) for urine (12 h after surgery). While both postoperative serum and urinary miR-21 levels can predict AKI development, urinary miR-21 especially 6 h after surgery is a more reliable marker than serum miR-21 for detection of established CSA-AKI (Tab. 1, Fig. 3, Ref. 43) . Text in PDF www.elis.sk. KEY WORDS: cardiac surgery, acute kidney injury (AKI), miRNA-21.
Introduction
Cardiac surgery-associated acute kidney injury (CSA-AKI) is common and has high mortality and morbidity rates (1) (2) (3) (4) . Management of SCA-AKI is costly and often the affected individuals run the risk of death due to electrolyte imbalance or excessive toxins in plasma (5) .
Early diagnosis of CSA-AKI is vital and can alter the prognosis of the diseases. It has been shown that postoperative changes in serum creatinine (sCr) levels are not reliable markers of CSA-AKI (4, 6) . SCr level usually rises in late stages of kidney injury when around 50 % of the kidney function is lost (7) .
Despite the fact that during recent years several studies have tried to introduce reliable markers such as cystatin C, kidney injury molecule-1 (Kim-1), neutrophil gelatinase-associated lipocalin (NGAL), etc. for early diagnosis or preventive treatment of CSA-AKI (8) (9) (10) (11) , no reliable marker exists for early diagnosis of CSA-AKI, and the researchers keep working on the available markers, their accuracy and prognostic value for diagnosis of CSA-AKI (12) (13) (14) (15) (16) .
MicroRNAs are post-transcriptional regulatory factors for gene expression. Their role has been shown in signaling cascades involved in the pathogenesis of renal diseases (17) . It has been proposed that a more specifi c biomarker, microRNA-21 (miR-21) has a role in mechanisms which are responsible in pathogenesis of AKI (18) .
AKI causes infl ammation as a result of damage to tubular epithelial cells (19) . The mechanism of infl ammation lies in the release of pro-infl ammatory mediators from injured tubular epithelial cells including interleukin-6 (IL-6), IL-1β, IL-8, tumor necrosis factor (TNF), transforming growth factor-β1 (TGF-β1), and monocyte chemotactic protein-1 (MCP-1) (18, 20, 21) .
After a severe AKI, fi brosis occurs in renal proximal tubules. The role of miR-21 in the process of fi brosis after AKI has been shown is several diseases (18) . Both infl ammation and fi brosis have roles in the pathogenesis of AKI, and miR-21 has a complicated role in both mechanisms. The overexpression of miR-21 has been shown in infl ammation and fi brosis following AKI (18, 22) .
One important mechanism of injury in CSA-AKI is ischemia reperfusion injury (4) . Some studies suggest a protective role for miR-21 during the short period after ischemia reperfusion injury (4, 18) . However, it seems that an imbalance in overexpression or underexpression of miR-21 may be involved in adverse outcomes in CSA-AKI (18) .
Increasing evidences are reported about the effectiveness of prophylactic usage of medications for prevention of CSA-AKI (23) (24) (25) . Therefore, fi nding reliable markers of CSA-AKI can be used for evaluation of the effectiveness of these medications and their mechanism of action (26) .
To the best of our knowledge only two studies have previously shown the role of miR-21 as a diagnostic biomarker for the detection of CSA-AKI (27, 28) .
In this regard Du et al have reported higher levels of serum and urine miR-21 in CSA-AKI patients 19.5 h after cardiac surgery (27) . Surprisingly, in another study, Gaede et al have recently reported that while the baseline (prior to surgery) serum miR-21 level was signifi cantly lower in CSA-AKI patients, its value did not differ 4 h after surgery between the patients with and without CSA-AKI (28) . Although both studies have reported the accuracy of miR-21 in prediction of CSA-AKI, no one has studied whether miR-21 can detect CSA-AKI before sCr increment.
Early detection of CSA-AKI is vital for the management of patients. Timing of renal replacement therapy in CSA-AKI is an important decision in the management of CSA-AKI in these patients. Preemptive renal replacement therapy is shown to improve the treatment results in CSA-AKI [29] . For early diagnosis and initiation of renal replacement therapy, reliable biomarkers of CSA-AKI are useful.
The aim of this study was to test the hypothesis that miR-21 can detect CSA-AKI earlier than sCr. To achieve this goal, we measured serum and urine concentrations of miR-21 in patients prior to, and 6, 12, and 24 h after cardiac surgery using real-time PCR.
Materials and methods

Ethics Statement
The study has been approved by the Ethical Committee of Hormozgan University of Medical Sciences, and adhered to the tenets of the Declaration of Helsinki. In addition, a written informed consent was obtained from all patients who accepted to participate in the study. Patients' information were kept confi dential.
Study design and patients
Based on the prevalence of AKI (5-45 %), a total of 103 consecutive patients (age 48-70 years) scheduled to undergo elective major cardiac surgery (coronary artery bypass grafting and/or valve replacement) between June and November 2015 with the use of extracorporeal circulation (ECC) at the Shahid Mohammadi Hospital, Bandar Abbas, Iran. The clinical history and results of physical examination, laboratory tests, echocardiography and coronary angiography were assessed for all patients. Cardiac surgery was performed according to the standard clinical practice.
The patients were divided into two groups according to whether or not developing AKI after cardiac surgery. Based on Kidney Disease Improving Global Outcomes (KDIGO) criteria (30) and the aim of this study (detection of AKI within 24 h postoperative period), AKI was defi ned as an increase in sCr > 0.3 mg/dl 24 h after surgery. Based on measured sCr of the 103 patients undergoing elective major cardiac surgery, 17 patients developed CSA-AKI. To match patients' age and sex, as well as some exclusion criteria, only 14 patients (7 male and 7 female) were included in AKI group. Sex and age matched patients who were showing no evidence of postoperative increase in sCr formed the non-AKI group (n = 14).
Inclusion and exclusion criteria
Based on the Cleveland clinic score, all candidates for open cardiac surgery who had not the risk factors including congestive heart failure, chronic obstructive pulmonary disease, infectious diseases, end-stage renal diseases, insulin-requiring diabetes, preoperative proteinuria, emergency surgery, and angiography within recent 72 hours were included in the study. Patients who avoided to complete written informed consent, and patients who had repeated cardiac surgery due to bleeding, as well as patients who their sCr levels increased within 48 or 72 h after cardiac surgery (18 and 3 Patients, respectively) were excluded from the study.
sample collection and Preparation
Urine and venous blood samples were collected 6 h prior to (baseline sample) and 6, 12, 24, 48 and 72 h after cardiac surgery. All samples were processed within 1 h after collection. Urine samples were centrifuged at 4 °C at 10000 g for 10 min and serum samples were centrifuged at 3000 rpm for 15 min. Aliquots of the samples were added to RNase/DNase-free tubes and stored at -80 °C (27) . SCr was determined 6 h prior to, and 24, 48 and 72 h after cardiac surgery using a 912 automatic biochemistry analyzer (Hitachi, Japan), and serum and urine miR-21 were measured 6 h prior to, and 6, 12 and 24 h after cardiac surgery using real-time PCR.
Real-time PCR
Total RNA was extracted from serum and urinary samples, using the miRneasy mini kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. The samples were spiked with 1 ng of C. elegans miR-39 mimic (cel-miR-39 miScript miRNA, Qiagen), as internal control miRNA.
For each sample, total RNA (1 μg) was reversely transcribed using miScript II RT cDNA synthesis Kit (Qiagen) according to the manufacturer's instructions. Each cDNA was used as a template for separate assay for miR-21 and cel-miR-39 quantitative real-time RT-PCR with miScript SYBR Green PCR Kit (Qiagen) using miScript primer assays (Qiagen) for human miR-21 and C. elegans miR-39 respectively. All reactions were performed in triplicate on a Corbett Rotor-Gene RG-6000 (Australia). The 2 −∆ct method, 2 −(CT[miR-21] -CT[cel-miR-39]) was used to evaluate the relative expression of miR-21 (27) . Group comparisons were expressed as mean 2 −∆ct ± SD.
Study statistics
For data analysis, IBM SPSS version 24.0 software were used. Shapiro-Wilks test was used to assess the normality of distribution of data. Repeated measures ANOVA with Bonferroni post hoc test were used for detection of sCr and miR-21 within and between groups differences. Categorical variables with nominal scales were determined using chi-square or Fisher's exact tests. Correlations were analyzed by Pearson correlation coeffi cient test. The performance of miR-21 as a predictor for the diagnosis of AKI, was determined using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. The optimal cut-off points were selected as the values that minimized the geometric distance from both 100% sensitivity and 100% specifi city on the ROC curves (27) . p value less than 0.05 was considered signifi cant.
Results
Patients characteristics
We .45 kg/m 2 , respectively. All CSA-AKI patients had a high level of sCr before their urinary output declined to the defi ned standard amount. At baseline, there was no signifi cant difference in sCr between the two groups ( Fig. 1) . Table 1 summarizes demographic variables in two study groups. Figure 2 shows serum and urinary levels of miR-21 before and after surgery in AKI and non-AKI groups. Real-time PCR analysis demonstrated that baseline serum level of miR-21 in AKI group was signifi cantly lower than non-AKI group (Fig. 2a ) (p = 0.009).
Serum concentration of miR-21 in AKI and non-AKI groups
As shown in Fig. 2a , in the AKI group, serum concentrations of miR-21 in 6, 12, and 24 h af ter surgery were decreased in comparison to those b efore surgery, but only this decrease was signifi cant 6 h after surgery samples (p = 0.008, p = 0.11, and p = 0.19, respectively).
There was no signifi cant difference between the serum miR-21 levels before and after surgery in non-AKI group.
Urine concentration of miR-21 in AKI and non-AKI groups
As shown in Fig. 2b , baseline urine concentration of miR-21 in AKI group was signifi cantly lower than in non-AKI group (p = 0.003). while urinary levels of miR-21 in AKI group were markedly decreased 6, 12, and 24 h after surgery compared with those before surgery (Fig. 2b) . These decrements were statistically signifi cant 6 and 12 h after surgery samples (p = 0.011, p = 0.015, and p = 0.056 respectively). No signifi cant difference was seen between the urinary miR-21 levels before and after surgery in non-AKI group (Fig. 2b) .
Performance of plasma and urine miR-21 concentrations for detection of AKI
ROC curve analysis re vealed that both postoperative serum and urine miR-21 concentrations can be used to detect AKI (Fig. 3) . The area under the RO C curves values (AUC) were 0.81 (95% CI: 0.65-0.97; p = 0.004) for serum miR-21 (6 h after surgery), 0.90 (95% CI: 0.79-0.99; p = 0.0001) for urine (6 h after surgery), and 0.86 (95% CI: 0.71-0.98; p = 0.001) for urine ( These data indicate that urine miR-21 concentrations especially 6 h after surgery is a more reliable marker than serum miR-21 for detection of established CSA-AKI. The ROC curve analysis showed that neither preoperative serum miR-21 nor preoperative urine miR-21 can predict CSA-AKI before surgery (AUC: 0.63, 95% CI: 0. 41-0.85; p = 0.12; and AUC: 0.70, 95% CI: 0.50-0.90; p = 0.09, respectively) ( Fig. 3) .
Correlation of miR-21 levels with age, ejection fraction, and duration of surgery and aorta clamp
Pearson correlation coeffi cient analysis identifi ed no significant correlation between serum or urine miR-21 levels with patient's age, ejection fraction, duration of bypass and duration of aorta clamp.
Discussion
CSA-AKI is an important complication of major cardiac surgeries. The defi nition of CSA-AKI based on the decrease in GFR or increase in creatinine level is not applicable for early diagnosis of CSA-AKI (6, 31, 32) . These markers are useful 24 h after cardiac surgeries. More rapid diagnostic tests or diagnostic models are needed to prevent AKI and to detect high-risk patients (14, (33) (34) (35) . While resent studies have proposed the accuracy of miR-21 in prediction of CSA-AKI (27, 28) , this accuracy to detect CSA-AKI during 24 h of postoperative period has been not fully investigated. The aim of this study was to test the hypothesis that miR-21 can detect CSA-AKI within 24 h after surgery, and before reliable sCr increment.
The main fi ndings of this study were as follows: fi rstly, patients with CSA-AKI had a lower serum and urinary levels of miR-21 than non-AKI developed patients; secondly, serum miR-21 expression level 6 h after cardiac surgery, and urinary miR-21 expression level 6 and 12 h after cardiac surgery were signifi cantly lower in AKI group than in non-AKI group; thirdly, while both postoperative serum and urinary miR-21 levels can predict AKI development, urinary miR-21 was a better predictor than serum miR-21.
These fi ndings are approximately in agreement with data published by Gaede et al who demonstrated a lower plasma level of miR-21 in patients with CSA-AKI before surgery (28) . The mentioned study was conducted on 115 patients, and CSA-AKI occurred in 3 6.5% of the patients. They measured plasma miR-21 before and 4 h after cardiac surgery and showed that while plasma miR-21 level was lower in both samples of CSA-AKI patients compared with non-AKI patients, it was only signifi cant before surgery (baseline) sample (28) . Gaede et al also proposed that baseline level of miR-21 can be considered as a predictive biomarker for CSA-AKI detection.
Results of the presen t study show that the lowest level of serum and urinary miR-21 are recorded 6 h after surgery, and during the next hours after surgery miR-21 levels tend to return to their normal levels. Serum and urinary miR-21 at 12 h after surgery were signifi cantly higher than those measured 6 h after surgery, as well as signifi cantly lower than those measured at 24 h after surgery. These fi ndings suggest that presumably miR-21 expression level is varied during the fi rst 24 h in patients with CSA-AKI.
The results of our study are completely inconsistent with data published by Du et al who reported a higher level of plasma and urine miR-21 in CSA-AKI patients 19.5 h after cardiac surgery (27) . While they demonstrated that postoperative overexpression of miR-21 can be used as a predictor to identify AKI, no information was reported about preoperative changes of miR-21 between AKI and non-AKI groups.
Results of performed studies dealing with changes of miR-21 expression during the course of kidney injuries are incompatible. In the context of pathophysiological role for miR-21 in kidney disease progression, there are two controversial approaches. In one approach, most studies believe that miR-21 has pro-infl ammatory and pro-apoptotic effects in kidney and its upregulation especially during ischemia-reperfusion induces cell injury and inhibits cell viability (27, (36) (37) (38) . In the other approach, several studies have suggested a reno-protective role for miR-21 and believe that upregulation of miR-21 plays a physiological role in protecting cells from acute injury by antiapoptotic effects and silencing metabolic functions. However, in chronic conditions, long-term elevation of miR-21 is detrimental and promotes cells toward infl ammation and fi brogenesis (39) (40) (41) (42) (43) .
To the best of our knowledge this is the fi rst data reporting postoperative decrement of miR-21 in CSA-AKI patients. However, our observation regarding preoperative decrement of miR-21 has been recently reported also by Gaede et al (28) . It has been shown that miR-21 is highly expressed in the healthy kidney and can respond very rapidly to cell stress because it is already present within epithelial cells (43) . It seems that that miR-21 is differentially expressed during different phases of renal injury. Our results suggest that presumably downregulation of miR-21 before and after cardiac surgery can make renal cells susceptible toward acute injury.
Studies on other biomarkers of AKI after major cardiac surgeries have shown that baseline renal function is an important factor in diagnostic accuracy of these biomarkers. Zhou et al have reported higher diagnostic accuracy for NGAL for diagnosis of CSA-AKI in individuals with normal baseline renal function (11) . In this study, we divided the patients based on their renal function to AKI and non-AKI group. One strength of our study is the evaluation of the levels of miR-21 biomarkers in the groups of patients with and without normal renal function 6, 12 and 24 h after cardiac surgery. This provides the possibility to compare the variations in miR-21 level in both groups. Although the variations in the levels of miR-21 in both groups of AKI and non-AKI patients had similar patterns after 6 hour, 12 hours, and 24 hours after cardiac surgery, the changes were more prominent in CSA-AKI group. Therefore, it seems that this biomarker is more accurate in AKI group in our study. This fact is shown in both urine and serum levels of miR-21. This is incompatible with the results by Zhou et al (11) . However, the fact that the study by Zhou et al is a meta-analysis on 4066 patients makes their results more reliable. Other fact is that NGAL and miR-21 are different biomarkers and their accuracy and the pattern of variations after cardiac surgeries are quite different.
Some recent available evidences from meta-analysis studies have reported successful usage of medications as prophylaxis of CSA-AKI in major cardiac surgeries. The mechanisms are poorly understood and may be related to increase in renal blood fl ow. Biomarkers like miR-21 which can predict CSA-AKI are ideal candidates for detecting the effectiveness of prophylaxis and understanding the respective mechanisms (23) .
Conclusion
We aimed to test the hypothesis that miR-21 can detect CSA-AKI in early hours after cardiac surgery. Based on obtained results, serum and urinary miR-21 expression levels 6 h after cardiac surgery were signifi cantly lower in AKI group than in non-AKI group. Moreover, while both postoperative serum and urinary miR-21 levels can predict AKI development, urinary miR-21 was a better predictor than serum miR-21. More studies with higher sample sizes are recommended.
